AGN:CSE; AGNPF:OTCQB; AGW:FSE

Algernon Pharmaceuticals Inc.

Algernon is a clinical stage drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Algernon has filed new intellectual property rights globally for its lead drug NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.
AGN:CSE AGNPF:OTCQB AGW:FSE

Expert Comments:

read more >

Clive Maund, CliveMaund.com

(1/12/22)
"Long-term charts show Algernon Pharmaceuticals Inc. stock to be very cheap. As it now has only 1.6M shares in issue after a 1 for 100 rollback, it has big upside potential. . .the company remains a Buy here and especially on any minor dips, if any."

read more >

Clive Maund, CliveMaund.com

(12/22/21)
"Algernon Pharmaceuticals Inc. stock has now arrived at what looks like a long-term cyclical low at the support at its late 2019 lows, which is a good point for it to turn, and that's what it looks like it is in the process of doing. . .the fundamentals of the company are believed to be positive. The conclusion is that Algernon is rated an attractive Speculative Buy here."

Clive Maund, CliveMaund.com

(12/12/21)
"Algernon Pharmaceuticals Inc. has some good things going on. The stock looks like it is at or close to a cyclical low, especially as volume has built up dramatically over the past month in a manner that is characteristic of a bottom, with upside volume kicking in in recent days. . .we could soon see some good gains in this stock."

headshot of André Uddin

André Uddin, Research Capital Corporation

(12/6/21)
"Algernon Pharmaceuticals Inc.'s Ifenprodil is in a Phase 2a trial in idiopathic pulmonary fibrosis/chronic cough. . .the company expects to complete patient enrollment of the study by 2021E, with results anticipated in Q2/22. . .Algernon is a Phase 2-stage drug development company, yet it has a market cap of CA$7M. We believe its risk/reward profile is attractive."

Algernon Pharmaceuticals will now pursue Ifenprodil in chronic cough based on encouraging recent study results in a Phase 2 trial.
read more >
Algernon Pharmaceuticals reported its acquisition of the exclusive rights from Dartmouth College for a method of use patent for use in treatment of neuroendocrine cancers expressing functional NMDA receptors.
read more >

André Uddin, Research Capital Corporation

(8/4/21)
Algernon Pharmaceuticals Inc. has decided to terminate the development of Ifenprodil for COVID-19. . .we agree with management that the risk-benefit profile of the COVID-19 program does not justify its continuation; we view the company's move as wise. . .Algernon is switching focus to the idiopathic pulmonary fibrosis/chronic cough indication."

Sam Riches, Weekend Dispensary

(5/22/21)
"Algernon Pharmaceuticals Inc. says it received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its planned Phase 1 clinical trial, which is set to begin later this year with the U.K.-based Hammersmith Medicines Research. . .Algernon believes its approach could potentially lead to a breakthrough therapy designation from the FDA, which enables priority review and can fast track the clinical trial process."

More Expert Comments

Experts Following This Company

Dr. KSS, Founder and Editor-in-Chief – BioPub.co
Clive Maund – CliveMaund.com
headshot of Penny Queen
Penny Queen, Mother, Investor and Social Media Leader
headshot of André Uddin
André Uddin – Research Capital Corporation

Company News 

1/19/2022 – Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study

1/14/2022 – Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study

12/8/2021 – Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2

12/2/2021 – Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial

11/30/2021 – Algernon Pharmaceuticals Announces New Chief Financial Officer

11/24/2021 – Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 1 Ifenprodil Small Cell Lung Cancer Study

11/23/2021 – Algernon Pharmaceuticals Announces Effective Date of Previously Announced Share Consolidation

11/19/2021 – Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study

11/1/2021 – Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study

10/21/2021 – Algernon Pharmaceuticals Announces Receipt of CAD$2M Cash Refund from Australian Research Program and Files Application to List its Common Shares on Nasdaq Capital Market

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.See disclaimer for more details.

Investing Highlights
 
Advancing new drug treatments for billion dollar global disease markets.
 
Conducting multiple phase II clinical trials
 
Experienced management team & globally recognized medical advisory board
catalyst Calendar
Q2
2021
U,S, FDA End-of-Phase 2 COVID-19 Study Meeting, Q2, 2021
Q4
2021
Phase 2 trial for IPF and chronic cough data expected Q4, 2021.
Q4
2021
Phase 1 Study planned for DMT, Q4 2021